{"abstract":"This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an start-up exclusive commercial license to Immunova Therapeutics, Inc., which is located in Houston, Texas, to practice the inventions embodied in the following patent applications and applications claiming priority to these applications:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2015/10/02/2015-24982.html","cfr_references":[],"citation":"80 FR 59797","comment_url":null,"comments_close_on":"2015-10-19","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 19, 2015 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2015-24982","effective_on":null,"end_page":59798,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2015/10/02/2015-24982.xml","html_url":"https://www.federalregister.gov/documents/2015/10/02/2015-24982/prospective-grant-of-a-start-up-exclusive-commercial-license-agreement-development-of-mhc-class-ii","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2015-24982?publication_date=2015-10-02","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2015-10-02/2015-24982/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":74,"last_updated":"2026-09-20 12:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2015-10-02/pdf/2015-24982.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2015-24982.pdf?1443703558","publication_date":"2015-10-02","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2015/10/02/2015-24982.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T04:55:03Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":59797,"subtype":null,"title":"Prospective Grant of a Start-up Exclusive Commercial License Agreement: Development of MHC Class II Restricted T Cell Epitopes From the Cancer Antigen, NY ESO-1, for the Treatment of Human Cancers","toc_doc":"Development of MHC Class II Restricted T Cell Epitopes from the Cancer Antigen, NY ESO1, for the Treatment of Human Cancers","toc_subject":"Exclusive Commercial License Agreements:","topics":[],"type":"Notice","volume":80}